The Indian Pharmacopoeia (IP) is published by the Indian Pharmacopoeia Commission (IPC) on behalf of Ministry of Health & Family Welfare, Government of India to fulfil the requirements of the Drugs and Cosmetics Act 1940. IP prescribes the official standards for drugs produced and/or marketed in India and thus contributes in the control and assurance of the quality of the medicines. The standards of the IP are authoritative and legally enforceable. It intends to help in the licensing of manufacturing, inspection and distribution of medicines in our country.

IP 2022 contains a total of 92 new monographs including 60 Chemical, 21 Vitamins, Minerals, Amino acids, Fatty acids etc., 3 Biotechnology-derived Therapeutic Products, 4 Human Vaccines, 2 Blood and Blood Related Products, 2 Herbs and Herbal Related Products, and 7 Phytopharmaceutical Ingredient Category monographs. This has led to the total number of 3152 monographs in the current edition of IP. In additions, 12 new general chapters have also been introduced.

Salient Features:

• New Monographs: 92 APIs: 27 Dosage Forms (Chemicals): 33
• Vitamins, Minerals, Amino acids, Fatty Acids etc.: 21
• Biotechnology Derived Therapeutic products: 03
• Herbs & Herbal Products: 02
• Blood & Blood Related Products: 02
• Vaccines and Immunosera for human use: 04
• New General Chapters: 12

 

Temporarily unavailable